Longitudinal analysis of genitourinary and bowel symptoms in prostate cancer patients following brachytherapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 1, 2010, Pages 1-10

  Eckman, Mark H ^a   Ying, Jun ^b   Hertzfeld, Kara ^c   Kumar, Nitin ^c   Barrett, William ^c  

^a Center for Clinical Effectiveness   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Brachytherapy; Genotyping; Outcomes research; Shared decision making

Indexed keywords

IODINE 125;

AGED; ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DYSURIA; HEMATURIA; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; NOCTURIA; PAINFUL DEFECATION; PROSTATE CANCER; RECTUM HEMORRHAGE;

ADENOCARCINOMA; AGED; BRACHYTHERAPY; COMORBIDITY; CONSTIPATION; DIARRHEA; ERECTILE DYSFUNCTION; GASTROINTESTINAL DISEASES; HUMANS; IODINE RADIOISOTOPES; LONGITUDINAL STUDIES; MALE; MALE UROGENITAL DISEASES; PROGNOSIS; PROSTATIC NEOPLASMS; RADIATION INJURIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 76749148608     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31819cd364     Document Type: Article

References (73)

1. Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148:435-448.
2. Barry MJ, Kaufman DS, Wu CL. A 55-Year Old Man with an Elevated Prostate-Specific Antigen Level and Early Stage Prostate Cancer. N Engl J Med. 2008;358:2161-2168.
3. Ragde H, Grado GL, Nadir B, et al. Modern prostate brachytherapy. CA Cancer J Clin. 2000;50:380-393.
4. Barry MJ, Albertsen PC, Bagshaw MA, et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer. 2001;91:2302-2314.
5. Middleton RG, Thompson IM, Austenfeld MS, et al. Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol. 1995;154: 2144-2148.
6. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med. 1997;44:681-692.
7. Diem SJ. How and when should physicians discuss clinical decisions with patients? J Gen Intern Med. 1997;12:397-398.
8. Elwyn G, Edwards A, Kinnersley P, et al. Shared decision making and the concept of equipoise: the competences of involving patients in healthcare choices. Br J Gen Pract. 2000;50:892-899.
9. Sheridan SL, Harris RP, Woolf SH. Shared decision making about screening and chemoprevention. A suggested approach from the US Preventive Services Task Force. Am J Prev Med. 2004;26:56-66.
10. Prostate Cancer Control Initiatives. Available at: http://www.cdc.gov/ cancer/ prostate/index.htm. Accessed February 11, 2005.
11. Singer PA, Tasch ES, Stocking C, et al. Sex or survival: trade-offs between quality and quantity of life. J Clin Oncol. 1991;9:328-334.
12. Litwin MS, Flanders SC, Pasta DJ, et al. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate qualityof- life analysis from CAPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1999;54:503-508.
13. Cassileth BR, Soloway MS, Vogelzang NJ, et al. Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res. 1992;1:323-329.
14. Lubeck DP, Litwin MS, Henning JM, et al. Measurement of health-related quality of life in men with prostate cancer: the CaPSURE database. Qual Life Res. 1997;6:385-392.
15. Lubeck DP, Grossfeld GD, Carroll PR. A review of measurement of patient preferences for treatment outcomes after prostate cancer. Urology. 2002;60(3 suppl 1):72-77; discussion 77-78.
16. Frosch DL, Kaplan RM, Felitti V. The evaluation of two methods to facilitate shared decision making for men considering the prostate-specific antigen test. J Gen Intern Med. 2001;16:391-398.
17. Colella KM, DeLuca G. Shared decision making in patients with newly diagnosed prostate cancer: a model for treatment education and support. Urol Nurs. 2004;24:187-191, 195-196.
18. Barry MJ. Health decision aids to facilitate shared decision making in office practice. Ann Intern Med. 2002;136:127-135.
19. Holm HH, Juul N, Pedersen JF, et al. Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol. 1983;130:283-286.
20. Hudson R. Brachytherapy Treatments Increasing Among Medicare Population. Baltimore, MD: Health Policy Brief of the American Urologic Association; 1999;IX(-9):1.
21. Jani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet. 2003;361:1045-1053.
22. Potters L, Morgenstern C, Calugaru E, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2008;179(suppl 5):S20-S24.
23. Stone NN, Potters L, Davis BJ, et al. Multicenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients with Gleason Score 7-10 Prostate Cancer Treated with Permanent Prostate Brachytherapy. Int J Radiat Oncol Biol Phys. 2009;73:341-346.
24. Zelefsky MJ, Hollister T, Raben A, et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000;47:1261-1266.
25. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007;67:327-333.
26. Joseph J, Al-Qaisieh B, Ash D, et al. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy. BJU Int. 2004;94:1235-1238.
27. Gelblum DY, Potters L, Ashley R, et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 1999;45:59-67.
28. Gelblum DY, Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48:119-124.
29. Lee WR, Hall MC, McQuellon RP, et al. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:614-623.
30. McElveen TL, Waterman FM, Kim H, et al. Factors predicting for urinary incontinence after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2004;59:1395-1404.
31. Merrick GS, Butler WM, Wallner KE, et al. Brachytherapy-related dysuria. BJU Int. 2005;95:597-602.
32. Merrick GS, Butler WM, Wallner KE, et al. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;62:437-447.
33. Merrick GS, Butler WM, Wallner KE, et al. Long-term urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;56:454-461.
34. Merrick GS, Butler WM, Wallner KE, et al. Dysuria after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;55:979-985.
35. Pisansky TM, Davis BJ, Stone NN. Morbidity after brachytherapy for prostate adenocarcinoma. Mayo Clin Proc. 2004;79:946 -947; author reply 947-949.
36. Stone NN, Stock RG. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy. Brachytherapy. 2003;2:32-39.
37. Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol. 1998;160:1379-1382.
38. Van Gellekom MP, Moerland MA, Van Vulpen M, et al. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry. Int J Radiat Oncol Biol Phys. 2005;63:772-780.
39. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341-1346.
40. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. Measurement Committee of the American Urological Association. J Urol. 1992;148:1558 -1563; discussion 1564.
41. Wehle MJ, Lisson SW, Buskirk SJ, et al. Prediction of genitourinary tract morbidity after brachytherapy for prostate adenocarcinoma. Mayo Clin Proc. 2004;79:314-317.
42. Kelly K, Swindell R, Routledge J, et al. Prediction of urinary symptoms after 125iodine prostate brachytherapy. Clin Oncol (R Coll Radiol). 2006;18:326-332.
43. Han BH, Demel KC, Wallner K, et al. Patient reported complications after prostate brachytherapy. J Urol. 2001;166:953-957.
44. Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003;21: 3979-3986.
45. Bottomley D, Ash D, Al-Qaisieh B, et al. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds. Radiother Oncol. 2007;82:46-49.
46. Davis JW, Kuban DA, Lynch DF, et al. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol. 2001;166:947-952.
47. Brandeis JM, Litwin MS, Burnison CM, et al. Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol. 2000;163:851-857.
48. Downs TM, Sadetsky N, Pasta DJ, et al. Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer- data from CaPSURE. J Urol. 2003;170:1822-1827.
49. Miller DC, Sanda MG, Dunn RL, et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 2005;23: 2772-2780.
50. Ash D, Bottomley D, Al-Qaisieh B, et al. A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localized prostate cancer. Radiother Oncol. 2007;84:135-139.
51. Buron C, Le Vu B, Cosset JM, et al. Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medicoeconomic study. Int J Radiat Oncol Biol Phys. 2007;67:812-822.
52. Ferrer M, Suarez JF, Guedea F, et al. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:421-432.
53. Hoffman RM, Hunt WC, Gilliland FD, et al. Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study. Cancer. 2003;97:1653-1662.
54. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2000;92:1582-1592.
55. Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899-905.
56. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250-1261.
57. Diggle PJ, Heagerty P, Liang KY, et al. Analysis of Longitudinal Data. 2nd ed. Oxford, England: Oxford University Press; 2002.
58. Fitzmaurice GM, Laird NM, Ware JH. Generalized estimating equations (GEE). Applied Longitudinal Data Analysis: Wiley Series in Probability and Statistics. New York, NY: John Wiley; 2004:291-321.
59. Ragde H. Prostate cancer brachytherapy. Semin Surg Oncol. 1997;13:389-390.
60. Frank I, Blute ML. Defining the appropriate patient population for primary brachytherapy for localized prostate cancer: work in progress. Mayo Clin Proc. 2004;79:307-308.
61. Haase O, Rodemann HP. Fibrosis and cytokine mechanisms: relevant in hadron therapy? Radiother Oncol. 2004;73(suppl 2):S144-S147.
62. Vozenin-Brotons MC, Milliat F, Sabourin JC, et al. Fibrogenic signals in patients with radiation enteritis are associated with increased connective tissue growth factor expression. Int J Radiat Oncol Biol Phys. 2003;56:561-572.
63. Anscher MS, Kong FM, Andrews K, et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 1998;41:1029-1035.
64. Martin M, Lefaix J, Delanian S. TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys. 2000;47:277-290.
65. Quarmby S, Fakhoury H, Levine E, et al. Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int J Radiat Biol. 2003;79: 137-143.
66. Saigal CS, Gornbein J, Nease R, et al. Predictors of utilities for health states in early stage prostate cancer. J Urol. 2001;166:942-946.
67. Gatti RA. The inherited basis of human radiosensitivity. Acta Oncol. 2001; 40:702-711.
68. Morgan JL, Holcomb TM, Morrissey RW. Radiation reaction in ataxia telangiectasia. Am J Dis Child. 1968;116:557-558.
69. Ramsay J, Birrell G, Baumann K, et al. Radiosensitive melanoma cell line with mutation of the gene for ataxia telangiectasia. Br J Cancer. 1998;77:11-14. (Pubitemid 28029766)
70. Ramsay J, Birrell G, Lavin M. Testing for mutations of the ataxia telangiectasia gene in radiosensitive breast cancer patients. Radiother Oncol. 1998;47:125-128.
71. Canman CE, Lim DS, Cimprich KA, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 1998;281:1677-1679.
72. Cesaretti JA, Stock RG, Lehrer S, et al. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int J Radiat Oncol Biol Phys. 2005;61:196-202.
73. Hall EJ, Schiff PB, Hanks GE, et al. A preliminary report: frequency of A-T heterozygotes among prostate cancer patients with severe late responses to radiation therapy. Cancer J Sci Am. 1998;4:385-389.